in ABCG2-overexpressing cells, MY-5445 selectively reverses ABCG2-mediated multidrug resistance. MY-5445 reverses ABCG2-mediated multidrug resistance (MDR) by potentiating the cytotoxicity of an ABCG2 substrate drug in ABCG2-overexpressing multidrug-resistant cancer cells, possibly by modulating the function and/or the protein expression of ABCG2[2]. In the S1-M1-80 cell, MY-5445 (3 μM; 48 hours) substantially increases the topotecan-induced apoptosis[2].

I.p administration of 0.5-3 mg/kg twice a day for 15 days) produces significant relief of mechanical hypersensitivity[3].